Animal Life Sciences develops nutritional and pharmaceutical treatments for cats and dogs by applying human cancer research technologies to veterinary medicine. The company addresses the high incidence of cancer in pets, with nearly 50% of dogs and 33% of cats over the age of 10 affected by the disease.
Funding
$60.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer is a leading cause of death in domestic animals, affecting a significant percentage of older dogs and cats. Veterinary medicine lags behind human medicine in applying advanced cancer research and treatments, creating an innovation gap in animal healthcare.
Solution
Animal Life Sciences develops nutritional and pharmaceutical treatments for cats and dogs, leveraging advancements in human cancer research technologies. The company licenses and commercializes safe and effective treatments, addressing the unmet needs in veterinary oncology. By applying breakthroughs from human drug development, Animal Life Sciences aims to bridge the innovation gap and improve the health outcomes for pets affected by cancer. The company is also developing a scientifically engineered pet food line for direct distribution to pet owners.
Target Audience
The primary target audience includes pet owners seeking advanced nutritional and pharmaceutical solutions for their cats and dogs, as well as veterinary professionals looking for innovative treatment options.
Features
- Licensing and development of pharmaceutical treatments based on human cancer research.
- Development of scientifically engineered and patented pet food products.
- Focus on nutritional and pharmaceutical solutions for cats and dogs.
- Collaboration with leading cancer research institutions such as MD Anderson Cancer Center.
- Partnerships with veterinary institutions like Texas A&M College of Veterinary Medicine.